blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2576540

EP2576540 - HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  02.08.2019
FormerGrant of patent is intended
Status updated on  19.03.2019
FormerExamination is in progress
Status updated on  18.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Sunovion Pharmaceuticals Inc.
84 Waterford Drive
Marlborough, MA 01752 / US
[2019/36]
Former [2013/15]For all designated states
Sunovion Pharmaceuticals Inc.
84 Waterford Drive
Marlborough, MA 01752 / US
Inventor(s)01 / CAMPBELL, John, Emmerson
581 Mount Auburn Street
Cambridge MA 02138 / US
02 / HEWITT, Michael, Charles
186 Holland Street
Unit 2
Somerville MA 02144 / US
03 / JONES, Philip
86 Sylvan Street
Danvers MA 01923 / US
04 / XIE, Linghong
20 Meeting House Lane
Southborough MA 01772 / US
 [2013/15]
Representative(s)Wallinger, Michael, et al
Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte Partnerschaft mbB
Zweibrückenstrasse 5-7
80331 München / DE
[2019/36]
Former [2014/02]Wallinger, Michael, et al
Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte
Zweibrückenstrasse 5-7
80331 München / DE
Former [2013/52]Savic, Bojan, et al
Jones Day
Rechtsanwälte Attorneys-at-Law Patentanwälte
Prinzregentenstraße 11
80538 München / DE
Former [2013/15]Ritter, Thomas Kurt, et al
Jones Day
Prinzregentenstraße 11
80538 München / DE
Application number, filing date11787386.926.05.2011
[2019/36]
WO2011US38057
Priority number, dateUS20100411410P08.11.2010         Original published format: US 411410 P
US20100348683P26.05.2010         Original published format: US 348683 P
[2013/15]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2011150156
Date:01.12.2011
Language:EN
[2011/48]
Type: A2 Application without search report 
No.:EP2576540
Date:10.04.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 01.12.2011 takes the place of the publication of the European patent application.
[2013/15]
Type: B1 Patent specification 
No.:EP2576540
Date:04.09.2019
Language:EN
[2019/36]
Search report(s)International search report - published on:KR19.04.2012
(Supplementary) European search report - dispatched on:EP04.11.2013
ClassificationIPC:C07D403/06, C07D471/04, C07D401/06, A61K31/498, A61K31/519, A61P25/00, C07D401/14, C07D405/14, C07D409/06, C07D413/06, C07D417/06, C07D471/14, C07D487/04, C07D491/056, C07D498/04, C07D498/14, C07D519/00, C07D409/14, C07D498/06
[2019/14]
CPC:
C07D498/06 (EP,US); A61K31/4164 (EP,US); A61K31/4178 (EP,US);
A61K31/4709 (EP,US); A61K31/498 (EP,US); A61K31/4985 (EP,US);
A61K31/506 (EP,US); A61K31/517 (EP,US); A61K31/5383 (EP,US);
A61P1/00 (EP); A61P1/08 (EP); A61P25/00 (EP);
A61P25/02 (EP); A61P25/04 (EP); A61P25/06 (EP);
A61P25/08 (EP); A61P25/14 (EP); A61P25/16 (EP);
A61P25/18 (EP); A61P25/20 (EP); A61P25/22 (EP);
A61P25/24 (EP); A61P25/28 (EP); A61P25/30 (EP);
A61P29/00 (EP); A61P3/00 (EP); A61P3/04 (EP);
A61P3/10 (EP); A61P43/00 (EP); C07D233/58 (EP,US);
C07D401/06 (EP,US); C07D401/14 (EP,US); C07D403/06 (EP,US);
C07D405/14 (EP,US); C07D409/06 (EP,US); C07D409/14 (EP,US);
C07D413/06 (EP,US); C07D417/06 (EP,US); C07D471/04 (EP,US);
C07D471/06 (EP,US); C07D471/14 (EP,US); C07D487/04 (EP,US);
C07D491/056 (EP,US); C07D498/04 (EP,US); C07D498/14 (EP,US);
C07D519/00 (EP,US) (-)
Former IPC [2013/15]C07D403/06, C07D471/04, C07D401/06, A61K31/498, A61K31/519, A61P25/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/15]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:HEZEROARYLVERBINDUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON[2013/15]
English:HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF[2013/15]
French:COMPOSÉS HÉTÉROARYLÉS ET LEURS PROCÉDÉS D'UTILISATION[2013/15]
Entry into regional phase06.12.2012National basic fee paid 
06.12.2012Search fee paid 
06.12.2012Designation fee(s) paid 
06.12.2012Examination fee paid 
Examination procedure06.12.2012Examination requested  [2013/15]
30.05.2014Amendment by applicant (claims and/or description)
04.08.2015Despatch of a communication from the examining division (Time limit: M06)
15.02.2016Reply to a communication from the examining division
24.05.2016Despatch of a communication from the examining division (Time limit: M06)
16.11.2016Reply to a communication from the examining division
29.03.2017Despatch of a communication from the examining division (Time limit: M06)
07.09.2017Reply to a communication from the examining division
05.02.2018Despatch of a communication from the examining division (Time limit: M04)
13.06.2018Reply to a communication from the examining division
16.10.2018Despatch of a communication from the examining division (Time limit: M04)
18.02.2019Reply to a communication from the examining division
20.03.2019Communication of intention to grant the patent
25.07.2019Fee for grant paid
25.07.2019Fee for publishing/printing paid
25.07.2019Receipt of the translation of the claim(s)
Divisional application(s)EP17205058.5  / EP3318561
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.08.2015
Opposition(s)05.06.2020No opposition filed within time limit [2020/33]
Fees paidRenewal fee
10.05.2013Renewal fee patent year 03
27.05.2014Renewal fee patent year 04
27.05.2015Renewal fee patent year 05
30.05.2016Renewal fee patent year 06
30.05.2017Renewal fee patent year 07
29.05.2018Renewal fee patent year 08
28.05.2019Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.05.2011
AL04.09.2019
AT04.09.2019
CY04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
MK04.09.2019
MT04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
TR04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
IE26.05.2020
LU26.05.2020
BE31.05.2020
CH31.05.2020
LI31.05.2020
[2022/32]
Former [2022/27]HU26.05.2011
AL04.09.2019
AT04.09.2019
CY04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
MT04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
TR04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
IE26.05.2020
LU26.05.2020
BE31.05.2020
CH31.05.2020
LI31.05.2020
Former [2022/26]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
TR04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
IE26.05.2020
LU26.05.2020
BE31.05.2020
CH31.05.2020
LI31.05.2020
Former [2021/24]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
IE26.05.2020
LU26.05.2020
BE31.05.2020
CH31.05.2020
LI31.05.2020
Former [2021/20]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
IE26.05.2020
LU26.05.2020
CH31.05.2020
LI31.05.2020
Former [2021/15]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
LU26.05.2020
CH31.05.2020
LI31.05.2020
Former [2021/12]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
CH31.05.2020
LI31.05.2020
Former [2021/08]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
CH31.05.2020
LI31.05.2020
Former [2020/37]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
Former [2020/36]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
Former [2020/27]AL04.09.2019
AT04.09.2019
CZ04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
PT06.01.2020
IS24.02.2020
Former [2020/25]AL04.09.2019
AT04.09.2019
CZ04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SK04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
PT06.01.2020
IS24.02.2020
Former [2020/24]AL04.09.2019
AT04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
PT06.01.2020
IS24.02.2020
Former [2020/23]AL04.09.2019
AT04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
PT06.01.2020
Former [2020/22]AL04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
PT06.01.2020
Former [2020/20]AL04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
Former [2020/15]AL04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
LT04.09.2019
LV04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
Former [2020/11]ES04.09.2019
FI04.09.2019
HR04.09.2019
LT04.09.2019
LV04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
Former [2020/10]FI04.09.2019
LT04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
Former [2020/09]FI04.09.2019
LT04.09.2019
NO04.12.2019
Former [2020/08]LT04.09.2019
NO04.12.2019
Documents cited:Search[X]US4036840  (O'BRIEN DARRELL E, et al) [X] 1-3,5,15,16 * compounds 3, 4, 12-20, 24-41, 43-51 *;
 [X]JPH0264553  (CANON KK) [X] 1,5,14 * first compound in page 483 *;
 [X]US5217980  (JANSSENS FRANS E [BE], et al) [X] 1,5 * intermediate 3, 12 , 17 *;
 [X]WO2004076451  (ALTANA PHARMA AG [DE], et al) [X] 1,2,5-7,10 * claim 1 and examples *;
 [X]WO2005030769  (ALTANA PHARMA AG [DE], et al) [X] 1,2,5-7,10 * CLAIM 1 AND EXAMPLES *;
 [X]WO2005061496  (ALTANA PHARMA AG [DE], et al) [X] 1,2,5-7,10 * 1, 2, 5-7, 10 *;
 [X]WO2006072828  (PFIZER PROD INC [US], et al) [X] 1,5,15,16 * claim 1 and examples and page 14 *;
 [X]WO2007077490  (PFIZER PROD INC [US], et al) [X] 1-16 * claim 1 and examples and page 14 *;
 [X]WO2007100880  (AMGEN INC [US], et al) [X] 1,5,15,16 * example 32, claim 19 *;
 [X]WO2007129183  (PFIZER PROD INC [US], et al) [X] 1,5,15,16 * claim 1 and 17 *;
 [X]WO2008020302  (PFIZER PROD INC [US], et al) [X] 1-16 * claim 1 and e.g. examples 1, 17 etc., claim 16 *;
 [X]WO2008046757  (HOFFMANN LA ROCHE [CH], et al) [X] 1,5 * claim 1 and examples *;
 [X]WO2009094442  (DOW AGROSCIENCES LLC [US], et al) [X] 1,5-10 * claim 1 and many examples e.g. 436, 465, 628, 699, 772 etc. *;
 [X]WO2009143156  (SEPRACOR INC [US], et al) [X] 1,2,5,12 * claim 1 and 50 and examples *;
 [I]WO2009152825  (LUNDBECK & CO AS H [DK], et al) [I] 1-16* claims 1 and 29 *;
 [XP]WO2010132999  (CHLORION PHARMA INC [CA], et al) [XP] 1,5-10 * claims 1 and 44 *;
 [XP]WO2011053559  (MERCK SHARP & DOHME [US], et al) [XP] 1,5,15,16 * claim 1 and page 2, lines 23-28 *;
 [X]  - REITER J ET AL, "On triazoles. XXXV. The reaction of 5-amino-1,2,4-triazoles with di- and triketones", JOURNAL OF HETEROCYCLIC CHEMISTRY, WILEY-BLACKWELL PUBLISHING, INC, US, (19950301), vol. 32, no. 2, doi:10.1002/JHET.5570320206, ISSN 0022-152X, pages 407 - 417, XP002322758 [X] 1-3,5 * compounds 8/4 and 8/5 in page 408 *

DOI:   http://dx.doi.org/10.1002/jhet.5570320206
 [X]  - KOLASA T ET AL, "Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (20000101), vol. 43, no. 4, doi:10.1021/JM9904102, ISSN 0022-2623, pages 690 - 705, XP002355625 [X] 1,5 * compounds and starting materials for compounds 10-11, 63-84, 87-93 *

DOI:   http://dx.doi.org/10.1021/jm9904102
International search[X]US2010028299  (EINAV SHIRIT [US], et al);
 [A]WO2010054067  (SCHERING CORP [US], et al);
 [A]WO2010054078  (SCHERING CORP [US], et al)
ExaminationFR2133979
 EP0447285
 WO9418200
 EP0634169
 WO9740050
 WO2004035522
 WO2004058760
 WO2004058759
 WO2004071447
 US2004242615
 WO2006116355
 WO2007124546
 WO2007137819
 WO2008038018
 WO2011072694
    - P. L. Trakhtenberg ET AL, "Electronic structure and reactivity of 2-[2-(4-R-2-quinolyl)vinyl]thiophenes and 5-[2-(4-R-2-quinolyl)vinyl]-2,2?-bithiophenes", Chemistry of Heterocyclic Compounds, (19790901), vol. 15, no. 9, doi:10.1007/BF00473838, ISSN 0009-3122, pages 970 - 975, XP055205154

DOI:   http://dx.doi.org/10.1007/BF00473838
    - Robert D. Schuetz ET AL, "An Investigation of Some Approaches to the Synthesis of [alpha]-Cyclodipolymethylenedithiophenes", The Journal of Organic Chemistry, (19620801), vol. 27, no. 8, doi:10.1021/jo01055a029, ISSN 0022-3263, pages 2841 - 2846, XP055205158

DOI:   http://dx.doi.org/10.1021/jo01055a029
    - ROBERTSON D W ET AL, "Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (19860101), vol. 29, no. 9, doi:10.1021/JM00159A004, ISSN 0022-2623, pages 1577 - 1586, XP008087539

DOI:   http://dx.doi.org/10.1021/jm00159a004
    - LIPSHUTZ B H ET AL, "METALATION STUDIES OF TRISUBSTITUTED OXAZOLES", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (19800101), vol. 46, doi:10.1021/JO00320A036, ISSN 0022-3263, pages 1410 - 1413, XP002301170

DOI:   http://dx.doi.org/10.1021/jo00320a036
    - WALKER K A M ET AL, "1-(NAPHTHYLALKYL)-1H-IMIDAZOLE DERIVATIVES, A NEW CLASS OF ANTICONVULSANT AGENTS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (19810101), vol. 24, no. 1, doi:10.1021/JM00133A015, ISSN 0022-2623, pages 67 - 74, XP002912929

DOI:   http://dx.doi.org/10.1021/jm00133a015
    - ZHANG X ET AL, "Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 15, no. 23, ISSN 0960-894X, (20051201), pages 5202 - 5206, (20051201), XP027801221
    - Kathrin Kutlescha ET AL, "An intermolecular C-C coupling reaction of iridium complexes", New Journal of Chemistry, GB, (20100101), vol. 34, no. 9, doi:10.1039/c0nj00158a, ISSN 1144-0546, page 1954, XP055441449

DOI:   http://dx.doi.org/10.1039/c0nj00158a
by applicantUS3536809
 US3598123
 US3845770
 US3916899
 US4008719
 US5059595
 US5073543
 US5120548
 US5134127
 US5354556
 US5591767
 US5639476
 US5674533
 US5733566
 WO2007129183
 WO2009152825
 WO2010034500
 WO2010126163
 WO2011072694
    - SODERLING et al., Proc. Natl. Acad. Sci., (19990000), vol. 96, pages 7071 - 76
    - LOUGHNEY et al., Gene, (19990000), vol. 234, pages 109 - 17
    - FUJISHIGE et al., J. Biol. Chem., (19990000), vol. 274, pages 18438 - 45
    - Harrison's Principles of Internal Medicine, (19910000), pages 93 - 98
    - WILLIAMS et al., J. of Med. Chem., (19990000), vol. 42, pages 1481 - 1485
    - BERGE et al., J. Pharm. Sci., (19770000), vol. 66, pages 1 - 19
    - HARPER, Progress in Drug Research, (19620000), vol. 4, pages 221 - 294
    - WANG et al., Curr. Pharm. Design, (19990000), vol. 5, pages 265 - 287
    - PAULETTI et al., Adv. Drug. Delivery Rev., (19970000), vol. 27, pages 235 - 256
    - MIZEN et al., Pharm. Biotech., (19980000), vol. 11, pages 345 - 365
    - GAIGNAULT et al., Pract. Med. Chem., (19960000), pages 671 - 696
    - ASGHARNEJAD et al., Transport Processes in Pharmaceutical Systems, Marcell Dekker, (20000000), pages 185 - 218
    - BALANT et al., Eur. J. Drug Metab. Pharmacokinet., (19900000), vol. 15, pages 143 - 53
    - BALIMANE; SINKO, Adv. Drug Delivery Rev., (19990000), vol. 39, pages 183 - 209
    - BROWNE, Clin. Neuropharmacol., (19970000), vol. 20, pages 1 - 12
    - BUNDGAARD, Arch. Pharm. Chem., (19790000), vol. 86, pages 1 - 39
    - BUNDGAARD, Controlled Drug Delivery, (19870000), vol. 17, pages 179 - 96
    - BUNDGAARD, Adv. Drug Delivery Rev., (19920000), vol. 8, pages 1 - 38
    - FLEISHER et al., Adv. Drug Delivery Rev., (19960000), vol. 19, pages 115 - 130
    - FLEISHER et al., Methods Enzymol., (19850000), vol. 112, pages 360 - 381
    - FARQUHAR et al., J. Pharm. Sci., (19830000), vol. 72, pages 324 - 325
    - FREEMAN et al., J. Chem. Soc., Chem. Commun., (19910000), pages 875 - 877
    - FRIIS; BUNDGAARD, Eur. J. Pharm. Sci., (19960000), vol. 4, pages 49 - 59
    - GANGWAR et al., Des. Biopharm. Prop. Prodrugs Analogs, (19770000), pages 409 - 421
    - NATHWANI; WOOD, Drugs, (19930000), vol. 45, pages 866 - 94
    - SINHABABU; THAKKER, Adv. Drug Delivery Rev., (19960000), vol. 19, pages 241 - 273
    - STELLA et al., Drugs, (19850000), vol. 29, pages 455 - 73
    - TAN et al., Adv. Drug Delivery Rev., (19990000), vol. 39, pages 117 - 151
    - TAYLOR, Adv. Drug Delivery Rev., (19960000), vol. 19, pages 131 - 148
    - VALENTINO; BORCHARDT, Drug Discovery Today, (19970000), vol. 2, pages 148 - 155
    - WIEBE; KNAUS, Adv. Drug Delivery Rev., (19990000), vol. 39, pages 63 - 80
    - WALLER et al., Br. J. Clin. Pharmac., (19890000), vol. 28, pages 497 - 507
    - GRAUER et al., "Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia", Journal of Pharmacology and Experimental Therapeutics, (20090000), vol. 331, no. 2, doi:doi:10.1124/jpet.109.155994, pages 574 - 90, XP008118361

DOI:   http://dx.doi.org/10.1124/jpet.109.155994
    - THRELFELL et al., "Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation", Journal of Pharmacology and Experimental Therapeutics, (20090000), vol. 328, no. 3, doi:doi:10.1124/jpet.108.146332, pages 785 - 95, XP008118360

DOI:   http://dx.doi.org/10.1124/jpet.108.146332
    - SCHMIDT et al., "Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia", Journal of Pharmacology and Experimental Therapeutics, (20080000), vol. 325, no. 2, doi:doi:10.1124/J.PET.107.132910, pages 681 - 90, XP002534689

DOI:   http://dx.doi.org/10.1124/J.PET.107.132910
    - JENS T. CARSTENSEN, Drug Stability: Principles & Practice, Marcel Dekker, (19950000), pages 379 - 80
    - STILL et al., J. Org. Chem., (19780000), vol. 43, page 2923
    - KITIGAWA et al., J. Med. Chem., (20070000), vol. 50, page 4710
    - Bioorg. Med. Chem. Lett., (20050000), vol. 15, pages 2679 - 84
    - J. Med. Chem., (20040000), vol. 47, pages 4494 - 4506
    - J. Org. Chem., (19900000), vol. 55, pages 2838 - 2842
    - Aust. J. Chem., (19930000), vol. 46, pages 987 - 93
    - Recueil des Travaux Chimiques des Pays-Bas, (19630000), vol. 82, pages 988 - 995
    - Chem. Ber., (19670000), vol. 100, pages 555 - 559
    - J. Mol. Structure, (19970000), vol. 415, pages 53 - 63
    - J. Org. Chem., (20020000), vol. 67, pages 1102 - 1108
    - Chem. Commun., (20090000), pages 2145 - 2147
 US20100348683
 US20100411410
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.